Literature DB >> 30891592

Haemadsorption improves intraoperative haemodynamics and metabolic changes during aortic surgery with hypothermic circulatory arrest.

Thomas Saller1, Christian Hagl2, Stefan Woitsch1, Yupeng Li3, Sebastian Niedermayer1, Frank Born2, Maximilian Luehr2, Tobias Kammerer1, Maximilian Pichlmaier2, Patrick Scheiermann1, Sven Peterss2.   

Abstract

OBJECTIVES: Aortic surgery involving hypothermic circulatory arrest (HCA) results in a systemic inflammatory response that may negatively influence outcome. An extracorporeal haemadsorption (HA) device (CytoSorb®) that removes inflammatory triggers may improve haemodynamic and metabolic reactions due to excessive inflammation and, ultimately, outcome.
METHODS: As a single-centre experience, the data of 336 patients who had undergone aortic surgery with HCA between 2013 and 2017 were retrospectively analysed. Patients with HA were matched to patients receiving standard therapy without HA (Control) by propensity score matching and compared subsequently.
RESULTS: During aortic surgery with HCA, HA significantly reduced the requirement of norepinephrine (HA: 0.102 µg/kg/min; Control: 0.113; P = 0.043). Severe disturbances of acid-base balance as reflected by a pH lower than 7.19 (HA: 7.1%; Control: 11.6%; P = 0.139), maximum lactate concentrations (HA: 3.75 mmol/l; Control: 4.23 P = 0.078) and the need for tris-hydroxymethylaminomethane buffer (HA: 6.5%; Control: 13.7%; P = 0.045) were less frequent with HA. Compared to standard therapy, HA decreased the need for transfusion of packed red blood cells (1 unit; P = 0.021) and fresh frozen plasma (3 units; P = 0.001), but increased the requirement of prothrombin complex concentrate (800 IE, P = 0.0036). HA did not affect inflammatory laboratory markers on the first postoperative day. Differences in operative mortality (HA: 4.8%; Control: 8.8%) and the length of hospital stay (HA: 13.5 days; Control: 14) were not statistically significant.
CONCLUSIONS: HA significantly reduces the need for vasopressors, the amount of transfusion and improves acid-base balance in aortic surgery with HCA. Multicentre prospective trials are required to confirm these results.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Anaesthesia; Aortic surgery; Circulatory arrest; Haemadsorption; Hypothermia; Inflammatory response; Vasoplegia

Mesh:

Year:  2019        PMID: 30891592     DOI: 10.1093/ejcts/ezz074

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  4 in total

Review 1.  Application of Adsorptive Blood Purification Techniques during Cardiopulmonary Bypass in Cardiac Surgery.

Authors:  Meng-Han Liu; Hong Yu; Rong-Hua Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-05-25       Impact factor: 7.310

2.  Prevention of vasoplegia with CytoSorb in heart failure patients undergoing cardiac surgery (CytoSorb-HF trial): protocol for a randomised controlled trial.

Authors:  Olga Papazisi; Eline F Bruggemans; Remco R Berendsen; Juan D V Hugo; Jan H N Lindeman; Saskia L M A Beeres; M Sesmu Arbous; Wilbert B van den Hout; Bart J A Mertens; Can Ince; Robert J M Klautz; Meindert Palmen
Journal:  BMJ Open       Date:  2022-09-19       Impact factor: 3.006

Review 3.  Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Marc Heymann; Raoul Schorer; Alessandro Putzu
Journal:  Acta Anaesthesiol Scand       Date:  2022-07-18       Impact factor: 2.274

4.  Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations.

Authors:  Kambiz Hassan; Tabea Brüning; Michael Caspary; Peter Wohlmuth; Holger Pioch; Michael Schmoeckel; Stephan Geidel
Journal:  Ann Thorac Cardiovasc Surg       Date:  2022-01-20       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.